Shirin Khan

2.0k total citations
19 papers, 1.5k citations indexed

About

Shirin Khan is a scholar working on Pharmacology, Cognitive Neuroscience and Experimental and Cognitive Psychology. According to data from OpenAlex, Shirin Khan has authored 19 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pharmacology, 9 papers in Cognitive Neuroscience and 7 papers in Experimental and Cognitive Psychology. Recurrent topics in Shirin Khan's work include Treatment of Major Depression (12 papers), Pain Management and Placebo Effect (7 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (5 papers). Shirin Khan is often cited by papers focused on Treatment of Major Depression (12 papers), Pain Management and Placebo Effect (7 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (5 papers). Shirin Khan collaborates with scholars based in United States, United Kingdom and India. Shirin Khan's co-authors include Walter A. Brown, Arif Khan, Arif Khan, Russell L. Kolts, Michael J. Detke, Craig Mallinckrodt, A Khan, Nayak L. Polissar, Earl L. Giller and Seth A. Cohen and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Neuropsychopharmacology.

In The Last Decade

Shirin Khan

18 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shirin Khan United States 13 690 577 442 367 316 19 1.5k
Arif Khan United States 20 827 1.2× 1.3k 2.2× 631 1.4× 355 1.0× 440 1.4× 42 2.4k
Amir H Kalali United States 26 459 0.7× 1.6k 2.8× 451 1.0× 316 0.9× 325 1.0× 84 2.5k
J.C. Ballenger United States 17 426 0.6× 555 1.0× 328 0.7× 273 0.7× 214 0.7× 174 1.7k
Bradley Witte United States 13 621 0.9× 933 1.6× 494 1.1× 631 1.7× 415 1.3× 16 2.1k
S.A. Montgomery United Kingdom 22 957 1.4× 1.0k 1.8× 582 1.3× 659 1.8× 250 0.8× 67 2.1k
Michael Philipp Germany 22 654 0.9× 845 1.5× 495 1.1× 664 1.8× 335 1.1× 82 2.2k
S. Hoog United States 12 655 0.9× 857 1.5× 832 1.9× 464 1.3× 192 0.6× 23 1.7k
Maurizio Fava United States 13 536 0.8× 461 0.8× 165 0.4× 414 1.1× 227 0.7× 17 1.2k
Venkat Bhat Canada 18 606 0.9× 426 0.7× 298 0.7× 292 0.8× 258 0.8× 97 1.6k
Diane McIntosh Canada 10 743 1.1× 496 0.9× 297 0.7× 419 1.1× 133 0.4× 18 1.5k

Countries citing papers authored by Shirin Khan

Since Specialization
Citations

This map shows the geographic impact of Shirin Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shirin Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shirin Khan more than expected).

Fields of papers citing papers by Shirin Khan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shirin Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shirin Khan. The network helps show where Shirin Khan may publish in the future.

Co-authorship network of co-authors of Shirin Khan

This figure shows the co-authorship network connecting the top 25 collaborators of Shirin Khan. A scholar is included among the top collaborators of Shirin Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shirin Khan. Shirin Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Khan, Arif & Shirin Khan. (2025). Placebo Response in Depression: A Perspective for Clinical Practice. Psychopharmacology Bulletin. 41(3). 91–98.
2.
Khan, Shirin, et al.. (2013). A New Flavonoidal Constituent from Taraxacum officinale (L.) Weber. Asian Journal of Chemistry. 25(7). 4117–4118. 1 indexed citations
3.
Khan, Shirin, et al.. (2012). Outcome measures and serious asthma exacerbation in clinical trials of asthma controller medications. Annals of Allergy Asthma & Immunology. 108(6). 448–453. 2 indexed citations
4.
5.
Cohen, Seth A., Brian Fitzgerald, Shirin Khan, & Arif Khan. (2004). The Effect of a Switch to Ziprasidone in an Adult Population With Autistic Disorder. The Journal of Clinical Psychiatry. 65(1). 110–113. 33 indexed citations
6.
Khan, Arif, Shirin Khan, Russell L. Kolts, & Walter A. Brown. (2003). Suicide Rates in Clinical Trials of SSRIs, Other Antidepressants, and Placebo: Analysis of FDA Reports. American Journal of Psychiatry. 160(4). 790–792. 251 indexed citations
7.
Cohen, Seth A., et al.. (2003). Weight, Lipids, Glucose, and Behavioral Measures With Ziprasidone Treatment in a Population With Mental Retardation. The Journal of Clinical Psychiatry. 64(1). 60–62. 33 indexed citations
8.
Khan, Arif, Michael J. Detke, Shirin Khan, & Craig Mallinckrodt. (2003). Placebo Response and Antidepressant Clinical Trial Outcome. The Journal of Nervous and Mental Disease. 191(4). 211–218. 126 indexed citations
9.
Detke, Michael J., et al.. (2003). . The Journal of Nervous and Mental Disease. 191(4). 211–218. 15 indexed citations
10.
Khan, Arif & Shirin Khan. (2003). Placebo in mood disorders: the tail that wags the dog. Current Opinion in Psychiatry. 16(1). 35–39. 7 indexed citations
11.
12.
Khan, Arif, et al.. (2002). An application of the revised CONSORT standards to FDA summary reports of recently approved antidepressants and antipsychotics. Biological Psychiatry. 52(1). 62–67. 8 indexed citations
13.
Khan, Arif, et al.. (2002). Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database. Journal of Affective Disorders. 68(2-3). 183–190. 132 indexed citations
14.
Khan, Arif, et al.. (2002). Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration Database. Journal of Clinical Psychopharmacology. 22(1). 40–45. 337 indexed citations
15.
Khan, Arif, Shirin Khan, & Walter A. Brown. (2002). Are placebo controls necessary to test new antidepressants and anxiolytics?. The International Journal of Neuropsychopharmacology. 5(3). 193–7. 102 indexed citations
16.
17.
Cohen, Seth A., et al.. (2001). Weight Gain With Risperidone Among Patients With Mental Retardation. The Journal of Clinical Psychiatry. 62(2). 114–116. 33 indexed citations
18.
19.
Mindham, R. H. S., et al.. (1991). A comparison of sulpiride, dothiepin, diazepam and placebo in the treatment of depressed out-patients. Journal of Psychopharmacology. 5(3). 259–262. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arif Khan Breakdown of academic impact, for papers by Amir H Kalali Breakdown of academic impact, for papers by J.C. Ballenger Breakdown of academic impact, for papers by Bradley Witte Breakdown of academic impact, for papers by S.A. Montgomery Breakdown of academic impact, for papers by Michael Philipp Breakdown of academic impact, for papers by S. Hoog Breakdown of academic impact, for papers by Maurizio Fava Breakdown of academic impact, for papers by Venkat Bhat Breakdown of academic impact, for papers by Diane McIntosh
Rankless by CCL
2026